Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

0.4803 +0.0003 (+0.06%)
Streaming Delayed Price Updated: 12:51 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeoVax Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Supply Chain
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
Addressing Critical U.S. Vulnerabilities in Vaccine Supply and National Preparedness 
Via TheNewswire.com
Topics Supply Chain
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
Process Expected to Increase Production Yield, Flexibility at Lower Cost 
Via TheNewswire.com
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy 
Via TheNewswire.com
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Advancements Position GEO-CM04S1 as a Leading Vaccine Candidate Addressing Unmet Medical Needs, Especially Among Immunocompromised Patients 
Via TheNewswire.com
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
Company to provide updates on progress toward the BARDA-funded Phase 2b trial of GEO-CM04S1, its next-generation COVID-19 vaccine as well as for Gedeptin® (solid tumor therapy) and GEO-MVA... 
Via TheNewswire.com
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
ATLANTA, GA - January 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced... 
Via TheNewswire.com
David Dodd, CEO of GeoVax Labs Inc. (NASDAQ: GOVX), to Present at NobleCon20
Via Investor Brand Network
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Participate in Upcoming Investor Conferences in September
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioMedNewsBreaks — GeoVax Labs Inc. (NASDAQ: GOVX) Enters $8.5M Registered Direct Offering with Institutional Investor
Via Investor Brand Network
Registration is Now Open for Tribe Public's Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Labs CEO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?
GeoVax Labs has seen its shares rise enormously over the past few days after an announcement from the World Health Organization relevant to one of its drugs. 
Via MarketBeat
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Update: GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee Review
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee Review
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Present at the Emerging Growth Conference on July 18, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Present at the Emerging Growth Conference on July 18, 2024
Company to Discuss Recent BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine and Provide Progress Update Across Its Clinical Development Pipeline 
Via TheNewswire.com
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
GeoVax to Raise Approximately $3.1 Million of Gross Proceeds in Offering Priced At-the-Market
ATLANTA, GA - (NewMediaWire) - July 11, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,... 
Via TheNewswire.com
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.